Spero Therapeutics (SPRO) EBT (2016 - 2026)

Spero Therapeutics has reported EBT for 11 years, with the latest figure at -$7.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 48.06% year-over-year to -$7.2 million; the trailing twelve-month figure through Mar 2026 stood at $15.5 million (up 121.07% YoY), and the FY2025 full-year result was $8.8 million, up 112.86% from the prior year.
• EBT for Q1 2026 stood at -$7.2 million, down from $31.8 million in the prior quarter.
• The five-year high for EBT was $55.5 million in Q4 2023, with the low at -$30.1 million in Q1 2022.
• Historically, EBT has averaged -$4.8 million across 5 years, with a median of -$11.9 million in 2023.
• Annual changes were most pronounced in 2024 — EBT sank 1669.41% — and 2025, when it soared 230.44%.
• Spero Therapeutics' EBT stood at $27.5 million in 2022, then soared by 101.91% to $55.5 million in 2023, then plunged by 143.9% to -$24.4 million in 2024, then soared by 230.44% to $31.8 million in 2025, then slumped by 122.66% to -$7.2 million in 2026.
• The last three EBT figures came in at -$7.2 million (Q1 2026), $31.8 million (Q4 2025), and -$7.4 million (Q3 2025), per Business Quant data.